CLCA125: Corpus Luteum and Uterine Artery Doppler With Serum P and CA125 in Threatened Abortion

Sponsor
Nesreen Abdel Fattah Abdullah Shehata (Other)
Overall Status
Completed
CT.gov ID
NCT02420769
Collaborator
Beni-Suef University (Other)
100
1
32
3.1

Study Details

Study Description

Brief Summary

The purpose of this study is to determine whether assessing color doppler of corpus luteum and uterine artery is useful in predicting patients who will complete pregnancy. The investigators will add to this the usefulness of serum progesterone and CA125 in prediction.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The introduction of Doppler ultrasound in obstetrics has allowed evaluating hemodynamic characteristics from the first trimester of pregnancy. For example, Kurjak et al.,in one of the first studies using transvaginal pulsed-wave Doppler ultrasound in early pregnancies, identified the uterine arteries in 100% of the patients. The flow blood of the corpus luteum was identified in 75% patients. The measures obtained by Doppler ultrasonography that may have prognostic value to the evolution of pregnancy include uteroplacental blood flow, also known as trophoblastic flow. Jaffe et al. reported that abnormal Doppler findings were associated with a significantly higher prevalence of complicated pregnancies, among women with abnormal Doppler findings, 43% ended in miscarriage, whereas among women with normal findings only 1.4% of women miscarried.Progesterone plays a crucial role in the maintenance of pregnancy. In the presence of sufficient progesterone levels during pregnancy, lymphocytes synthesize a mediator called progesterone induced blocking factor (PIBF), which is anti-abortive in mice . Besides inducing secretary changes in the endometrium and supporting early pregnancy, it modulates the maternal immune response to prevent fetal rejection and relaxes the uterine smooth muscles .CA-125, well-known as a tumor marker for epithelial ovarian cancer , is a high molecular weight glycoprotein that is produced not only by ovarian cancer, but also by nonovarian tumors, normal epithelia of the peritoneum, the endometrium, the fallopian tube, and the ovary. Because CA-125 is also produced by the endometrium, some authors suggest that CA-125 can be used as a marker for endometrial receptivity in patients undergoing IVF . Its role as a predictor for pregnancy outcome is controversial .

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    100 participants
    Observational Model:
    Other
    Time Perspective:
    Prospective
    Official Title:
    Color Doppler of CL and Uterine Artery With Serum Progesterone and CA125 in Threatened Abortion
    Study Start Date :
    Sep 1, 2014
    Actual Primary Completion Date :
    May 1, 2017
    Actual Study Completion Date :
    May 1, 2017

    Arms and Interventions

    Arm Intervention/Treatment
    Threatened abortion

    Pregnant patients > 8 weeks gestation coming to the ANC clinic with mild vaginal bleeding but healthy viable intrauterine pregnancy. Vaginal color doppler for uterine artery and corpus luteum together with serum progesterone and CA125 will be assessed.

    Outcome Measures

    Primary Outcome Measures

    1. Viable fetus (According to WHO viable fetus >500 gm or > 20 weeks) [from 20 weeks till 21 weeks gestation]

      The investigators will assess how many patients in both groups reached viability of fetus. According to WHO viable fetus >500 gm or > 20 weeks.

    Secondary Outcome Measures

    1. Resistance index of uterine artery and corpus luteum [from 8 weeks till 20 weeks]

      Vaginal color doppler of uterine artery and corpus luteum for all pregnant patients in the study at first visit in ANC clinic .

    2. serum CA125 and progesterone [from 8 weeks till 20 weeks gestation]

      serum CA125 and progesterone will be done for all pregnant patients at first visit in ANC clinic

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    20 Years to 40 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • patients with pregnancy between 8 to 20 weeks of gestation,

    • who were diagnosed with threatened abortion.

    Exclusion Criteria:
    • patients with multiple pregnancies,

    • molar pregnancy,

    • ectopic pregnancy,

    • amenorrhea with different etiologies of pregnancy,

    • maternal history of systemic diseases and uterine anatomic abnormalities

    • patients who did not have their outcome data through week 20 of gestation due to relocation.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Beni-Suef University Cairo Egypt 018

    Sponsors and Collaborators

    • Nesreen Abdel Fattah Abdullah Shehata
    • Beni-Suef University

    Investigators

    • Principal Investigator: Nesreen A Shehata, MD, Beni-Suef University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Nesreen Abdel Fattah Abdullah Shehata, Assisstant professor of Obstetrics and Gynecology, Beni-Suef University
    ClinicalTrials.gov Identifier:
    NCT02420769
    Other Study ID Numbers:
    • Beni-Suef 9
    First Posted:
    Apr 20, 2015
    Last Update Posted:
    Dec 7, 2017
    Last Verified:
    Dec 1, 2017
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Keywords provided by Nesreen Abdel Fattah Abdullah Shehata, Assisstant professor of Obstetrics and Gynecology, Beni-Suef University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Dec 7, 2017